1. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly 
Eva C Coopmans, Aart J van der Lely, Joppe J Schneiders, Sebastian J C M M Neggers 
The Lancet Diabetes & Endocrinology 
Volume 7, Issue 6, Pages (June 2019)
DOI: /S (19)
Copyright © 2019 Elsevier Ltd Terms and Conditions

2. Figure
Representative T2-weighted MRI scans from two patients, at baseline and during pasireotide long-acting release (PAS-LAR) treatment
Region of interest adenoma to normal pituitary ratio at baseline was 1·05 for patient 1 and 1·34 for patient 2. This signal increased to 1·63 for patient 1 and 1·85 for patient 2 during PAS-LAR treatment.
The Lancet Diabetes & Endocrinology 2019 7, DOI: ( /S (19) )
Copyright © 2019 Elsevier Ltd Terms and Conditions